

Cloning and recombinant expression of rat and human kynureninase

Salvatore Toma^a, Masayuki Nakamura^c, Shigenobu Toné^d, Etsuo Okuno^c, Ryo Kido^c, Jerome Breton^a, Nilla Avanzi^a, Liviana Cozzi^a, Carmela Speciale^b, Marina Mostardini^b, Silvia Gatti^b, Luca Benatti^{b,*}

^aBioscience Center, Pharmacia and Upjohn, Via Pasteur 10, 20014 Nerviano, Italy

^bCNS Research, Pharmacia and Upjohn, Via Pasteur 10, 20014 Nerviano, Italy

^cDepartment of Biochemistry, Wakayama Medical College, 27 Kyubanchō, Wakayama 640, Japan

^dTokyo Metropolitan Institute of Medical Science, Tokyo 113, Japan

Received 24 February 1997; revised version received 20 March 1997

Abstract Kynureninase [E.C.3.7.1.3.] is one of the enzymes involved in the biosynthesis of NAD cofactors from tryptophan through the kynurenine pathway. By tryptic and CNBr digestion of purified rat liver kynureninase, we obtained about 28% of the amino acid sequence of the enzyme. The rat kynureninase cDNA, isolated by means of reverse-transcribed polymerase chain reaction and hybridization screening, codes for a polypeptide of 464 amino acids. Northern blot analysis revealed the synthesis of a 2.0 kb rat kynureninase mRNA. A cDNA encoding human liver kynureninase was also isolated. The deduced amino acid sequence is 85% identical to that of the rat protein. COS-1 cells were transfected with both cDNAs. The K_m values of the rat enzyme, for L-kynurenine and DL-3-hydroxykynurenine, were $440 \pm 20 \mu\text{M}$ and $32 \pm 5 \mu\text{M}$ and of the human enzyme $440 \pm 20 \mu\text{M}$ and $49 \pm 6 \mu\text{M}$, respectively. Interestingly, COS-1 cells transfected with the cDNA coding for rat kynureninase also display cysteine-conjugate β -lyase activity.

© 1997 Federation of European Biochemical Societies.

Key words: Kynurenine; Kynurenic acid; Excitatory amino acid; Neuroprotection; Cysteine-S-conjugate β -lyase; Quinolinic acid

1. Introduction

Kynureninase [L-kynurenine hydrolase E.C.3.7.1.3] catalyzes the conversion of L-3-hydroxykynurenine (3-OHKYN) and L-kynurenine (L-KYN) to 3-hydroxyanthranilic acid (3-OHAA) and anthranilic acid (AA), respectively [1]. The reaction is pyridoxal-5'-phosphate (PLP) dependent and is sensitive to nutritional vitamin B6 deprivation in mammals [2]. The biochemical properties of kynureninase were studied in mouse, rat and pig liver extracts [3–6] showing that this enzyme is an homodimer of around 95 kDa. It is present in all major classes of vertebrates [7] and can be regarded as a 3-hydroxykynureninase-type enzyme, since it hydrolyzes preferentially 3-OHKYN [8]. The product of this reaction, 3-OHAA is further utilised to synthesize quinolinic acid (QUINA), whose neurotoxic effect in the CNS is well documented [9]. On the other hand, L-KYN can be converted by kynurenine aminotransferase to produce kynurenic acid (KYNA), a neuroprotective agent [1]. Therefore, increases in KYNA concentrations within the central nervous system could mitigate the neurotoxic effects of QUINA while reductions in KYNA levels could promote excitotoxicity. Intraperitoneal injection of a

kynureninase inhibitor *o*-methoxybenzoylalanine (oMBA), increases the concentration of KYNA in the hippocampal extracellular space and is able to prevent audiogenic convulsions in DBA/2 mice [10]. This, among other evidence [11], suggests that the pharmacological modulation of the kynurenine pathway could have neuroprotective effects. A substantial increase in the kynureninase activity has been observed in several cerebral and systemic inflammatory conditions [12]. In addition, it has been recently found that interferon- γ induces kynureninase activity in murine macrophages [13] and kynureninase mRNA in human monocyte/macrophages [14]. Moreover, recent *in vivo* data [15] suggested either the existence of two kynureninase enzymes or the presence of different regulatory co-factors of the enzymatic activity in liver and brain tissues. The cloning and characterization of kynureninase cDNA expression is therefore instrumental for clarifying the function of this enzyme, the existence of possible tissue-specific isoforms, the regulation of its expression by immune stimuli and its possible involvement in disorders associated with unbalanced levels of QUINA and KYNA. To gain insights into the physiology and pathology of the kynurenine pathway we have recently isolated the cDNAs encoding two other enzymes: kynurenine aminotransferase [16] and kynurenine 3-hydroxylase [17]. Here we report the molecular cloning of rat and human kynureninase and their biochemical characterization in transiently transfected COS-1 cells. The constitutive expression of rat kynureninase mRNA is also demonstrated in liver, kidneys, brain and other tissues by reverse-transcribed polymerase chain reaction (RT-PCR) and Northern blot analysis.

2. Materials and methods

2.1. Partial amino acid sequence of rat liver kynureninase

Rat liver kynureninase was purified to homogeneity as previously described [18]. Both the intact enzyme and the protein electroblotted onto PDVF membrane, were subjected to Edman's degradation. Next, 500 pmol of purified rat kynureninase were digested by trypsin and CNBr, and the samples were subjected to reverse-phase HPLC (column 4.6×250 mm, Biofine RPC-SC18 or YMC-c4). The resulting polypeptide fragments were identified and collected. Sequence analysis was performed by Edman's degradation in a gas-phase sequencer (Applied Biosystems, Foster City, CA). Several peptide sequences were obtained: *M1*: CSYKYLNSGAGGLAGAFIHEKHAHTIKPALVGX; *M2*: FGHELSTRFNM; *M3*: VKTYLEELDK; *M4*: AKIGAYGHEVGKRPX; *M5*: IIGDESI; *M6*: IKPREGEETLR; *M7*: AKIGAY; *M8*: KDIVGAHEKEIA; *M9*: EPSLELPDVRRIATELNCDP; *T1*: HAHTIKPALVGXFGHELSTR; *T2*: FNMDNK; *T3*: TYLEELDKXAKIGAYGHEVGK; *T4*: PXIIGDESI; *T5*: LDEEDKLK; *T6*: VAPVPLYNSFHDVYK; *T7*: LQLIPGVNGFR; *T8*: AFPSDHYAIEHQI; *T9*: DLPSIDSLVNEDDNAIYFLGN; *T10*: SILLTGYLEYL. CNBr peptides are de-

*Corresponding author. Fax: (39) 2-48383965.
E-mail: luca.benatti@eu.pnu.com

noted with a prefix *M*, and tryptic peptides with a prefix *T*. Amino acids are named using the one-letter code.

2.2. Rat and human kynureninase cDNA clones selection from λ gt11 phage libraries of liver cDNA

A 96-bp-long fragment of the rat kynureninase cDNA was obtained by RT-PCR as follows. Reverse transcription was performed using rat liver poly(A)⁺ mRNA, obtained using oligo (dT)-cellulose spin columns (Pharmacia Biotech, Uppsala, Sweden) on total RNA, extracted according to the RNazol method (Cinna/Biotex Lab, TX). Reverse transcription and PCR were performed as previously described [19,20]. Two amino acid sequences from the least degenerated regions of the following overlapping peptides: M1, M2, T1 and T2, were selected to design degenerated oligonucleotides: 5'-GC(G,A,T,C)-TT(T,C)AT(A,T,C)CA(T,C)GA(A,G)AA(A,G)CA-3' (sense orientation) based on the peptide sequence AFIHEKH and 5'-(T,C)-TT(A,G)TT(A,G)TCCAT(A,G)TT(A,G)AA(G,A,C,G)C-3' (antisense orientation) based on the peptide sequence RFNMDNK. The product of the amplification was gel-purified and sequenced using the Sequenase Kit (United States Biochemicals Corp., Cleveland, OH).

Rat and human cDNA libraries were constructed starting from 1 μ g of liver poly(A)⁺ mRNA in λ gt11 essentially as previously described [21]. The 96-bp PCR product was used as a probe to screen under stringent conditions the rat liver λ gt11 cDNA library. More than 20 positive clones were obtained and the one with the longest insert was selected. The λ phage DNA was digested with *Eco*RI and the insert was purified by gel electrophoresis and subcloned into a Bluescript SK phagemid (Stratagene, La Jolla, CA). Sequencing was carried out with universal and gene specific primers. Oligonucleotides were synthesised using the 394 DNA/RNA Synthesizer (Applied Biosystem, Foster City, CA) and purified with Sephadex G25 columns (Pharmacia Biotech, Uppsala, Sweden). The screening of the human liver cDNA library was performed using the rat full-length cDNA as ³²P-labelled probe. The insert was cleaved from the positive human clones with *Eco*RI restriction enzyme and subcloned into a Bluescript SK vector (Stratagene, La Jolla, CA).

2.3. RT-PCR study and Northern blot analysis of rat kynureninase mRNA expression in different tissues

Rat poly(A)⁺ mRNA from different tissues (Clontech, Palo Alto, CA) was treated for 30 min with RNase-free DNase (Stratagene, La Jolla, CA) at 37°C to remove any residual genomic DNA. Messenger RNA samples were reverse transcribed at 37°C for 60 min. The reaction mixture contained 250 ng of poly(A)⁺ mRNA, 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl₂, 4 mM DTT, 0.5 mM each dNTP, 30 U of RNase Inhibitor (Promega, Madison, WI), 100 pmol of random examers (Promega, Madison, WI) and 200 U Superscript Reverse Transcriptase (GIBCO Life Tech., Gaithersburg, MA), in a final volume of 30 μ l. The reverse transcription step was omitted in PCR controls from each RNA sample to check for the presence of contaminating genomic DNA. Three microliters of each cDNA were used for the PCR reaction. The PCR mix contained 0.2 μ M of upstream and downstream primers 5'-CAACTATGACTGCGCTGAGG-3'; 5'-GTTCTCGCTTGTACAGACG-3', 200 μ M of each dNTP, 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 2 mM MgCl, 2.5 U of Amplitaq (Perkin Elmer Cetus, Norwalk, CT). Thermal cycling was performed as follows: 1 min at 94°C, 1 min at 60°C, 2 min at 72°C for 30 cycles. For the Northern Blot analysis: a commercial filter (Clontech, Palo Alto, CA) containing 2 μ g per lane of poly(A)⁺ mRNA

from different rat tissues was hybridised under stringent conditions with the ³²P-labelled 96-bp PCR product used for the screening of the rat library.

2.4. Recombinant expression of rat and human kynureninases in COS-1 cells and enzymatic assays

The rat and human kynureninase cDNAs were inserted into the *Xho*I site of the eukaryotic expression vector pSVL (Pharmacia Biotech, Uppsala, Sweden). Inserts were obtained by means of PCR and specific 5' and 3' primers. The following oligonucleotides were used: 5'-TGTCTCGAGCTGATGGAGCCCTCGCT-3' (sense) and 5'-TGTCTCGAGGGCTAGTTTCTTCTGTAG-3' (antisense) for rat kynureninase; 5'-TGTCTCGAGGTAATGGAGCCTTCATCT-3' (sense); 5'-TGTCTCGAGTGCTAATTTTGTCTTCTG-3' (antisense) for human kynureninase. The identity of the PCR fragments was verified by DNA sequencing of both strands. COS-1 cells (1 500 000/75 cm²), grown in DMEM medium, were transfected with 10 μ g of pSVL-rat or pSVL-human kynureninase DNA using the calcium phosphate method [22]. Seventy-two hours after transfection, cells were disrupted by 4 cycles of freezing and thawing. After centrifugation of the lysate (15000 \times g for 30 min) the supernatant was stored at -20°C and used for the enzymatic assay.

Kynureninase activity was assayed according to Kawai et al. [23]. The assay mixture contained 2 mM of L-KYN or DL-3OHKYN, 20 μ M of PLP in 50 mM Tris buffer (pH 8.5), and the reaction was stopped with TCA 8.3% (w/v), at different times after incubation at 37°C and centrifuged. The supernatant was applied to a C18 reversed-phase column (201TP54, 4.6 \times 25 cm, Vydac Separation Group, CA) and eluted isocratically at a flow rate of 1 ml/min with a mobile phase consisting of 80 mM potassium phosphate (pH 2.5), 17% (v/v) acetonitrile. AA or 3-OHAA were measured with a fluorescence detector on line (Waters 414, Waters Corporation, MA) set at λ_{ex} = 313 nm and λ_{em} = 420 nm. The detection was about 60-fold less sensitive for 3-OHAA than for AA in these experimental conditions. Kinetic constants were calculated with a non-linear regression program (Sigma-Plot) using the Michaelis-Menten equation. Notably, kynureninase has been shown to be specific for the L-forms of 3OHKYN whereas the D-forms are neither substrates nor inhibitors of the enzyme [1]. Since in this work the racemic (DL) form of 3OHKYN was used, the reported K_m values should accordingly be divided by a factor of two to obtain the correct K_m for L-3OHKYN.

Cysteine-conjugate β -lyase activity was measured using a coupled assay as described by Abraham and Cooper [24]. The reaction mixture, consisting of 50 mM Tris buffer (pH 8.5), 2 mM S-(1,2-dichlorovinyl)-L-cysteine (DCVC), 0.5 mM α -keto- γ -methylbutyrate, 0.1 mM PLP, was incubated for 0, 30, 60 min prior to the incubation of the reaction product with 1.8 U alanine dehydrogenase with addition of 0.3 mM NADH and 0.1 M ammonium acetate. Absorbance at 340 nm was measured using a microplate reader. All reagents were from Sigma if not otherwise indicated.

3. Results and discussion

Rat liver kynureninase was purified to homogeneity from the liver homogenate supernatant with a 1286-fold enrichment of the kynureninase activity in the final fraction [18]. No sequence information could be obtained after Edman's degra-

Table 1

Kinetic properties of recombinant human and rat kynureninase expressed in COS-1 cells and measured in presence of 20 μ M PLP

	Human kynureninase		Rat kynureninase		
	V_{max} (μ M/min)	K_m (μ M)	V_{max} (μ M/min)	K_m (μ M)	K_i (μ M)
L-KYN	0.7 \pm 0.07	438 \pm 20	1.46 \pm 0.01	440 \pm 20	2.4 \pm 0.2
DL-3OHKYN	4.3 \pm 0.2	49 \pm 6	4.2 \pm 0.1	32 \pm 5	13 \pm 4

K_m were determined measuring kynureninase activity at 10 different concentrations of L-KYN (range 10 μ M to 10 mM) and six different concentrations of DL-3HOKYN (range 10 μ M to 0.5 mM). Protein concentration for rat and human kynureninase assay were 0.78 mg/ml and 0.18 mg/ml, respectively.

For the rat enzyme, reaction rate was also measured in presence of *o*-(methoxybenzoyl)alanine (5 μ M) with L-KYN and DL-3OHKYN concentrations in the range of the K_m values.

Results are the mean \pm SEM of three experiments.

TTG AAA AGG TAC TGG AAA CTG AGG ACC CTA TCT GGA TCA AAG CAG TTT CTG	ATG GAG CCC TCG CCT CTT GAG CTA CCA GTT GAT GCA GTG	90
	Met Glu Pro Ser Pro Leu Glu Leu Pro Val Asp Ala Val	
CGG CGC ATC GCG GCT GAA CTC AAT TGT GAC CCA ACC GAT GAG AGG GTG GCT	CTC CGC TTG GAT GAG GAA GAT AAA CTG AAG CGT TTT AAG	180
Arg Arg Ile Ala Ala Glu Leu Asn Cys Asp Pro Thr Asp Glu Arg Val Ala	Leu Arg Leu Asp Glu Glu Asp Lys Leu Lys Arg Phe Lys	
GAC TGT TTT TAT ATC CCC AAA ATG CGG GAC CTG CCT TCA ATT GAT CTA TCT	TTA GTG AAT GAG GAT GAT AAT GCC ATC TAT TTC CTG GGA	270
Asp Cys Phe Tyr Ile Pro Lys Met Arg Asp Leu Pro Ser Ile Asp Leu Ser Leu Val Asn	Glu Asp Asp Asn Ala Ile Tyr Phe Leu Gly	
AAT TCC CTT GGT CTT CAA CCG AAG ATG GTT AAA ACA TAC CTG GAG GAA GAG	CTA GAT AAG TGG GCC AAA ATA GGA GCC TAT GGC CAT GAG	360
Asn Ser Leu Gly Leu Gln Pro Lys Met Val Lys Thr Tyr Leu Glu Glu Glu Leu Asp	Lys Trp Ala Lys Ile Gly Ala Tyr Gly His Glu	
GTA GGG AAA CGT CCT TGG ATT ATA GGA GAT GAG AGC ATT GTA ECG	CTT ATG AAG GAC ATT GTA GGA GCC CAT GAG AAA GAA ATA GCT CTA	450
Val Gly Lys Arg Pro Trp Ile Ile Gly Asp Glu Ser Ile Val Thr Leu Met Lys	Asp Ile Val Gly Ala His Glu Lys Glu Ile Ala Leu	
ATG AAT GCT TTG ACT GTT AAT TTA CAT CTC CTG CTG TTA TCA TTC TTT	AAG CCT ACA CCA AAG CGG CAC AAA ATT CTT CTA GAA GCC AAA	540
Met Asn Ala Leu Thr Val Asn Leu His Leu Leu Leu Leu Ser Phe Phe Lys	Pro Thr Pro Lys Arg His Lys Ile Leu Leu Glu Ala Lys	
GCC TTC CCT TCT GAT CAT TAT GCG ATC GAG TCA CAG ATT CAA CTT	CAT GGA CTT GAT GTT GAG AAA AGT ATG CGG ATG ATA AAG CCA CGA	630
Ala Phe Pro Ser Asp His Tyr Ala Ile Glu Ser Gln Ile Gln Leu His Gly	Leu Asp Val Glu Lys Ser Met Arg Met Ile Lys Pro Arg	
GAG GGG GAA GAG ACC TTA AGA ATG GAG GAC ATA CTG GAA GTA ATT	GAG AAG GAA GGA GAC TCA ATT GCT GTG GTC CTG TTC AGT GGC CTG	720
Glu Gly Glu Glu Thr Leu Arg Met Glu Asp Ile Leu Glu Val Ile Glu Lys	Glu Gly Asp Ser Ile Ala Val Leu Phe Ser Ser Leu Leu	
CAC TTT TAT ACT GGA CAG CTG TTC AAC ATT CCT GCC ATT ACA CAA	GCC GGA CAT GCA AAG GGC TGT TTT GTT GGC TTT GAC CTA GCG CAT	810
His Phe Tyr Thr Gly Gln Leu Phe Asn Ile Pro Ala Ile Thr Gln Ala Gly	His Ala Lys Gly Cys Phe Val Gly Phe Asp Leu Ala His	
GCG GTT GGA AAT GTT GAA CTC CAC TTA CAT GAC TGG GAT GTT GAC	TTT GCC TGC TGG TGC TCC TAC [*] AAG TAT TTA AAT TCA GGA GCT GGA	900
Ala Val Gly Asn Val Glu Leu His Leu His Asp Trp Asp Val Asp Phe Ala	Cys Trp Cys Ser Tyr Lys Tyr Leu Asn Ser Gly Ala Gly	
GGT CTG GCT GGT GCC TTC ATC CAT GAG AAA CAC GCT CAC ACG ATC	AAG CCA GCG TTA GTG GGA TGG TTC GGC CAT GAA CTC AGT ACA AGA	990
Gly Leu Ala Gly Ala Phe Ile His Glu Lys His Ala His Thr Ile Lys	Pro Ala Leu Val Gly Trp Phe Gly His Glu Leu Ser Thr Arg	
TTT AAC ATG GAT AAC AAA CTA CAA TTA ATC CCC GGG GTC AAT	GGA TTC CGA ATT TCC AAC CCT CCC ATT CTG TTG GTC TGC TCC TTG CAT	1080
Phe Asn Met Asp Asn Lys Leu Gln Leu Ile Pro Gly Val Asn Gly Phe Arg	Ile Ser Asn Pro Pro Ile Leu Leu Val Cys Ser Leu His	
GCC AGT TTA GAG ATC TTT CAG CAA GCA ACT ATG ACT GCG CTG AGG	AGA AAA TCC ATT CTG CTG ACA GGT TAT CTG GAA TAC TTG CTC AAA	1170
Ala Ser Leu Glu Ile Phe Gln Gln Ala Thr Met Thr Ala Leu Arg Arg Lys	Ser Ile Leu Leu Thr Gly Tyr Leu Glu Tyr Leu Leu Lys	
CAT TAC CAT GGC GGA AAT GAC ACA GAA AAC AAG AGG CCA GTT	GTG AAC ATA ATC ACC CCA TCC AGA GCA GAG GAA CGA GGC TGC CAG CTG	1260
His Tyr His Gly Gly Asn Asp Thr Glu Asn Lys Arg Pro Val Val Asn	Ile Ile Thr Pro Ser Arg Ala Glu Glu Arg Gly Cys Gln Leu	
ACA CTG ACC TTT TCC ATT TCC AAG AAA GGC GTT TTT AAG GAA	CTA GAA AAA AGA GGA GTC GTC TGT GAC AAG CGA GAA CCA GAA GGC ATC	1350
Thr Leu Thr Phe Ser Ile Ser Lys Lys Gly Val Phe Lys Glu Leu Glu Lys	Arg Gly Val Val Cys Asp Lys Arg Glu Pro Glu Gly Ile	
CGG GTG GCC CCG GTT CCT CTC TAT AAT TCT TTC CAT GAT GTT	TAT AAG TTC ATC AGA CTG CTT ACT GCC ATA CTC GAC TCT ACA GAA AGA	1440
Arg Val Ala Pro Val Pro Leu Tyr Asn Ser Phe His Asp Val Tyr Lys	Phe Ile Arg Leu Leu Thr Ala Ile Leu Asp Ser Thr Glu Arg	
AAC TAG CCA TGC TTT CTA AAT AAC TCA AGT AAA TCT CAC ACA	CTG GGG GTT CCA CTT CTA CTG CAT TTT AGT CAT TCA AAA GTC TCC AGA	1530
Asn		
AAT TGA TGG CAT AGA AAT GAT GAT GAT TTT ATA AAC TTA	CAT AAA ACC TGG TAC ATG TTT TAA TAT CTG TGT CGC TGA TGT GCT GTG GAC	1620
TAA GAA GTC ACA TTT TAC ATG ACT CCA ACC TAC AGA TGA	CTG TCT TGA TCA GCT GTC ACC TTC CAT GGT CAC TGA AAG GTT GTG TGT TTA	1710
ATT TGT GAC TGA AAT GAC AAC ATT AAA ATG TAT CTG GAC	TTC TTG TAT AAA AAA A	1765

Fig. 1. Nucleotide sequence and predicted primary amino acid sequence of rat kynureninase. Regions of alignment with trypsin and CNBr cleavage fragments are underlined. The PLP binding region is underlined twice. The asterisk shows the lysine involved in the PLP binding. Triplets coding for amino acids which differ from those observed by Takeuchi et al. [25] are boxed (GeneBank accession number U68168).

dation of the purified protein, indicating that the NH₂-terminus is probably modified as a result of a post-transcriptional event. This data is in agreement with the study of Takeuchi et al. [25] which demonstrates the presence of a *N*-acetylmethionine at the N-terminal residue of the protein purified from rat liver. Several peptide sequences were obtained from the purified rat kynureninase (Fig. 1). Degenerated oligonucleotides were designed from the amino acid sequences of peptides M1, M2, T1 and T2 and they were used as primers for RT-PCR of rat liver cDNA (see Section 2 for details). The resulting 96-bp cDNA product was used to screen a rat liver cDNA library and to isolate a full-length rat kynureninase cDNA clone (Fig. 1). The rat kynureninase cDNA is 1765 nucleotides long. It contains a unique translation initiation site in position 52 and an open reading frame coding for a protein of 464 amino acid residues. The comparison of the rat kynureninase predicted sequence and the primary sequence of the native protein [25], shows two major differences: alanine instead of threonine (residue 18) and threonine instead of serine (residue 118). Notably, we also found an alanine residue in position 18 in the native protein (see peptide M9 sequence). Moreover, the-

onine in position 18 was found to be modified with an unknown group [25]. Whether these differences reflect the presence of two functionally distinct isoforms of the enzyme deserve further investigation. The tissue distribution of rat kynureninase mRNA was analyzed by Northern blot and RT-PCR. Fig. 2 shows the constitutive presence in liver and kidney, of a single kynureninase transcript, approximately 2.0 kb long. The RT-PCR analysis (Fig. 3), which is more sensitive than Northern blot, shows that rat kynureninase mRNA is also detectable in heart, retina, ovary, lung, testis and brain, consistent with the organ distribution of the kynureninase activity [23].

The rat kynureninase cDNA was used as probe to screen a human liver cDNA library and to isolate a cDNA clone corresponding to the human kynureninase (see Section 2 for details). The rat and human kynureninase cDNAs show a 70% identity at the nucleotide level (not shown) and 85% of identity at the protein level (Fig. 4). While this manuscript was in preparation, the cDNA sequence of the human kynureninase was reported [26]. No differences can be observed between the published human kynureninase cDNA sequence [26] and the




Fig. 2. Northern blot analysis of rat kynureninase mRNA in various rat tissues (adult Sprague-Dawley). Lanes: 1, heart; 2, brain; 3, spleen; 4, lung; 5, liver; 6, skeletal muscle; 7, kidney; 8, testis. RNA size (kb) is shown on the left.

one we refer to. A comparison of the human kynureninase cDNA sequence with the EST databank at NIH resulted in the detection of several sequences (accession No. R27138, R11005, among others) containing either the 5' or the 3' untranslated region of human kynureninase. These cDNA fragments were obtained from placenta and liver/spleen of a male fetus indicating the constitutive expression of the kynureninase mRNA in these human tissues. Interestingly, two putative proteins (Fig. 4) predicted on the base of the *Caenorhabditis elegans* chromosome III (accession No. U56965) and of the *Saccharomyces cerevisiae* chromosome XII (accession No. U19027) DNA sequence, exhibit high degree of homology with rat and human kynureninase. In particular, the region of the proteins containing the PLP-binding site (Lys²⁷⁶ in the rat sequence): FACWCSYKY is conserved among the four sequences (Fig. 4). Based upon sequence comparison we propose that these unidentified sequences encode *S. cerevisiae* and *C. elegans* kynureninase.

To further confirm that the isolated cDNAs encoded rat and human kynureninase the two cDNAs were subcloned into the pSVL expression vector and transfected to COS-1 cells. Kynureninase and hydroxykynureninase activities were detected in transfected COS-1 cells (Table 1). No activity was observed in cells transfected with the antisense cDNAs. Table 1 shows the kinetic properties of the two enzymes. Kynureninase activity was measured at different concentrations of L-KYN (from 0.01 to 10 mM). K_m values obtained for both recombinant proteins are similar to the values published for

the rat native [5] and human recombinant enzymes [26]. Notably, when DL-3OHKYN was used as substrate, the kinetic of the reaction could be considered linear only during the first 6 min of reaction. At longer reaction time we could observe a decrease of the reaction velocity compatible, as reported for the native enzyme [3], with an inhibitory effect of the reaction product: 3-OHAA. With DL-3OHKYN as substrate, the K_m for both rat and human enzymes was about 10-fold lower and the V_{max} about 5-fold higher than using L-KYN. The rat kynureninase and hydroxykynureninase activities were inhibited by oMBA [10], a competitive inhibitor of kynureninase, with a half-maximal inhibitory value of 2.4 μ M (L-KYN) and 13 μ M (DL-3OHKYN) respectively. Optimum pH was found to be around 9.0 for both rat and human kynureninase using L-KYN and around 8.5 with DL-3OHKYN confirming the property of the native protein [7].

A major route of detoxication for many halogenated xenobiotics is by conjugation to the tripeptide glutathione. Subsequent metabolic processing of such conjugates yields the cysteine conjugate of the original chemicals, which then may serve as substrate for enzymes that express β -lyase activity. Recently, attention has been directed toward the toxicological importance of these enzymes because β -lyase action can yield toxic metabolites [27]. The PLP-binding site of rat kynureninase (Fig. 1) is similar to the one present in the γ family of PLP-dependent enzymes, which contains proteins with β -lyase activity [25]. Notably, COS-1 cells transfected with the rat kynureninase cDNA showed a cysteine-conjugate β -lyase specific activity of 1.97 nmol min⁻¹ mg⁻¹ using DCVC as substrate. No activity was present in cells transfected with the antisense cDNA. Fig. 4 shows that the four polypeptide sequences contain an almost identical PLP-binding site region. Being this region common also to aminotransferases with cysteine conjugate β -lyase activity, it is likely that also human, and putative *S. cerevisiae* and *C. elegans* kynureninases possess such an enzymatic activity. Apart from kidney, β -lyase activity is also found predominantly in the liver. As shown in Fig. 2, these are the tissues with higher levels of kynureninase mRNA. Cysteine S-conjugates readily cross the blood-brain barrier [28]. Inactivation of kynureninase in the brain by cysteine S-conjugates could therefore profoundly affect the cerebral level of kynurenine and its neurotoxic/neuroprotective metabolites.

Chiarugi and coworkers investigated the effect of oMBA on kynurenine metabolism in vivo [15]. As expected, oMBA significantly decreased the brain content of AA, the product of kynureninase activity. Unexpectedly, brain content of 3-OHAA, the product of hydroxykynureninase, was not modified by the treatment. Moreover, in vitro inhibition studies with oMBA indicated different IC₅₀ values when enzyme




Fig. 3. RT-PCR analysis of rat kynureninase mRNA in different rat tissues (adult Sprague-Dawley). Lanes: 1, negative control; 2, brain; 3, heart; 4, retina; 5, testis; 6, ovary; 7, liver; 8, lung; 9, kidney. PCR products were electrophoresed on 2% agarose gel, blotted into nitrocellulose membrane and hybridized with 5'-end-P³² labelled oligonucleotide: 5'-TCTCCGCTTGGATGAGGAAGAT-3'. Southern Blot results are shown. This a qualitative assay and the relative amount of the PCR products obtained cannot be compared among different tissues.

rlkynase	M--EPSPLE-	----LPVDA-	----VRRIAA	ELNC-DPTDE	RVALRLDEED	37
hlkynase	M--EPSSE-	----LPADT-	----VQRIAA	ELKC-HPTDE	RVALHLDEED	37
C15H9.7	MSDAPPQPEN	EQECMCTQDK	VLQFLNKMAD	ESGIKDLTDP	ALAEFLSDSD	50
L8083.14	M-----	-----	-----	-----E	K-ALELDGEY	11
rlkynase	KLKRFKDCFY	IPKMRDLPSI	DLSLVNEDDN	AIYFLGNSLG	LQPKMVKTYL	87
hlkynase	KLRHFRECFY	IPKIQDLPPV	DLSLVNKDEN	AIYFLGNSLG	LQPKMVKTYL	87
C15H9.7	ALKEIRDLFH	YPKAGTLPDA	DPSLVDPESD	SIYLCGNSLG	LMPKATGEVM	100
L8083.14	P-ESLRDEFN	IPTFKSM---	--GLSSDDKP	VTYLCGNSLG	LMPKSTRNSI	55
rlkynase	EEELDKWAKI	GA---YGH--	-EVGKRPIII	GDESIVTLMK	DIVGAHEKEI	131
hlkynase	EEELDKWAKI	AA---YGH--	-EVGKRPIIT	GDESIVGLMK	DIVGANKEKEI	131
C15H9.7	KDHLDKWAKM	GV---FGH--	-MSGEPWAH	CDEYCLEGVG	RLVGAKEKEV	144
L8083.14	NAELDAWSDC	AVESHFKHPE	EARGKVPWVS	IDLPILPLLA	PIVGAQENEV	105
rlkynase	ALMNALTVNL	HLLLSFFKP	TPKRHKILLE	AKAFPSDHYA	IESQIQLHGL	181
hlkynase	ALMNALTVNL	HLLLSFFKP	TPKRYKILLE	AKAFPSDHYA	IESQLQLHGL	181
C15H9.7	SVCNSLTVNI	HVLLTSFYKP	TETRHKILLE	SKAFPSDHYA	IESQIRLKGR	194
L8083.14	AVMNSLTANL	NSLLITFYKP	TEKRFKILFE	KGSFSPDYA	FYNQCKIHGI	155
rlkynase	-DVEKSMRMI	KPREGEETLR	MEDILEVIEK	EGDSIAVVLF	SGLHFYTGQL	230
hlkynase	-NIEESMRMI	KPREGEETLR	IEDILEVIEK	EGDSIAVILF	SGVHFYTGQH	230
C15H9.7	-TVQDSMVCL	EPREGEETLR	TEDILDYIEK	NGDEIAIVFF	SGIQYYTGQL	243
L8083.14	SEPENVFIQI	EPREGETYIR	TQDILDITIEV	NQDELALVCL	SGVQYYTGQY	205
rlkynase	FNIPAITQAG	HA-KGCFVGF	DLAHAVGNVE	LHLHDWDVDF	ACWCSYKYLN	279
hlkynase	FNIPAITKAG	QA-KGCVVGF	DLAHAVGNVE	LYLHDWGVDF	ACWCSYKYLN	279
C15H9.7	FDMRAITEAG	HR-KGCFVGF	DLAHAFANVP	LHLHWDVDF	ACWCSYKYGC	292
L8083.14	FDIGRITSFA	HQFPDILVGW	DLAHAVGNVP	LQLHDWGV-F	ACWCSYKYLN	254
rlkynase	SGAGGLAGAF	IHEKHAH---	-----	-----TIK--	-PALVGWFGH	308
hlkynase	AGAGGIAGAF	IHEKHAH---	-----	-----TIK--	-PALVGWFGH	308
C15H9.7	TGAGSIGGLF	VHERFLN---	-----	-----DQR--	-ERMLGWWSH	321
L8083.14	AGPGGIGGLF	VHSKHTKPDP	AKESLPRLAG	WVGNDPAKES	LPRLAGWGN	304
rlkynase	ELSTRFNMDN	KLQLIPGVNG	FRISNPPILL	VCSLHASLEI	FQK-ATMTAL	357
hlkynase	ELSTRFKMDN	KLQLIPGVCG	FRISNPPILL	VCSLHASLEI	FKQ-ATMKAL	357
C15H9.7	KMSSRFVMDN	VLDLDEGAAG	YRISNPPIHT	VAAMLGSLKV	FDQ-VSLENL	370
L8083.14	DPAKRFQMLE	VFEPIPGALG	FRQSNPSVID	TVALRSSLEL	FAKFNGINEV	354
rlkynase	RRKSILLTGY	LEYLLKHY-H	GGNDTE-NKR	P-VVNIITPS	RA-EERGCQL	403
hlkynase	RKKSIVLLTGY	LEYLIKHN-Y	GKDKAA-TKK	P-VVNIITPS	HV-EERGCQL	403
C15H9.7	RSRSCYLTGY	LEYLVKTL-F	GENSEQRTTK	L-SISIITPE	EF-HQRCQQL	417
L8083.14	RKRSLLLTNY	MTELEASKY	YKHPRLIEKL	PCFFTTILTPT	STDEEHGAQL	404
rlkynase	TLTF-SISKK	G-----VFKE	LEKRGVCDK	REPEGIRVAP	VPLYNSFHDV	447
hlkynase	TITF-SVPNK	D-----VFQE	LEKRGVCDK	RNPNGIRVAP	VPLYNSFHDV	447
C15H9.7	SLKF-SSPID	I-----IYPE	LVKRGCAVDK	RYPNVIRVAP	VHLYNNYVDI	461
L8083.14	SLYFDSDTGK	EDIMPKVFQY	LHDHGVIGDA	RPNVIRLAP	APLYNTFSDV	454
rlkynase	YKFIRLLTAI	LDSTE-RN				464
hlkynase	YKFTNLLTSI	LDSAETKN				465
C15H9.7	RRFISVLQEV	AHIVE-SE				478
L8083.14	YIAVNALNEA	MD----KL				468

Fig. 4. Alignment of the rat and human kynureninase primary amino acid sequences with the predicted sequence of two putative proteins: L8083.14 and C15H9.7 obtained from the *Saccharomyces cerevisiae* chromosome XII and the *Coenorhabditis elegans* chromosome III, respectively. *rlkynase*, rat kynureninase; *hlkynase*, human kynureninase. Conserved amino acids among all proteins are shaded.

preparation from liver and brain tissues where used. This would suggest either the existence of two kynureninase enzymes or the presence of different enzyme modulators in peripheral and brain tissues. Our data clearly demonstrate that the isolated liver cDNA, when transfected to COS-1 cells,

possess both kynureninase and hydroxykynureninase activities. However, we cannot exclude the presence of brain-specific kynureninase isoform(s) displaying different substrate specificity. This study analyses the molecular and biochemical properties of rat and human liver kynureninases providing an

initial step to understand the pathophysiological role of this enzyme and to design more specific inhibitors with neuroprotective potential.

Acknowledgements: We thank Dr. M. Serena Fabbrini for critical reading of the manuscript and J. Maliszko for the oligonucleotide synthesis.

References

- [1] T.W. Stone, *Pharmacol. Rev.* 45 (1993) 309–378.
- [2] J.L. Vandekamp, A. Smolen, *Pharmacol. Biochem. Behav.* 51 (1995) 753–758.
- [3] C.E. McDermott, D.A. Casciano, F.H. Gaertner, *Biochem. Biophys. Res. Comm.* 51 (1973) 813–818.
- [4] F. Takeuchi, H. Otsuka, Y. Shibata, *J. Biochem. (Tokyo)* 88 (1980) 987–994.
- [5] J.L. Stevens, *J. Biol. Chem.* 260 (1985) 7945–7950.
- [6] K. Tanizawa, K. Soda, *J. Biochem. (Tokyo)* 85 (1979) 901–906.
- [7] F.H. Gaertner, A.S. Shetty, *Biochim. Biophys. Acta* 482 (1977) 453–460.
- [8] J.F. Reinhard, J.B. Erickson, E.M. Flanagan, *Adv. Pharmacol.* 30 (1994) 85–127.
- [9] Schwarcz, R., Guidetti, P. (1996) in: (M. Aschner and H.K. Kimelberg, Eds.), *The Role of Glia in Neurotoxicity*, CRC Press, Boca Raton, FL, pp. 245–267.
- [10] A. Chiarugi, R. Carpenedo, M.T. Molina, L. Mattoli, R. Pellicciari, F. Moroni, *J. Neurochem.* 65 (1995) 1176–1183.
- [11] Speciale, C., Salvati, P., Cini, M., Benatti, L., Tamburin, M., Molinari, A., Rosa, B., Allievi, C., Caccia, C., Varasi, M. and Post, C. (1996) *Soc. Neurosci. Abst.* 608.9.
- [12] M.P. Heyes, K. Saito, E.O. Major, S. Milstein, S.P. Markey, J.H. Vickers, *Brain* 116 (1993) 1425–1450.
- [13] D. Alberati-Giani, P. Ricciardi-Castagnoli, C. Kohler, A. Cesura, *J. Neurochem.* 66 (1996) 996–1004.
- [14] Mostardini, M., Ferrario, R.G., Caccia, C., Speciale, C. and Benatti, L. (1996) *Soc. Neurosci. Abst.* 706.1.
- [15] A. Chiarugi, R. Carpenedo, F. Moroni, *J. Neurochem.* 67 (1996) 692–698.
- [16] M. Mosca, L. Cozzi, J. Breton, C. Speciale, E. Okuno, R. Schwarcz, L. Benatti, *FEBS Lett.* 353 (1994) 21–24.
- [17] Magagnin, S., Bormetti, R., Speciale, C., Cini, M., and Benatti, L. (1996) *Soc. Neurosci. Abst.* 608.4.
- [18] Lee, S.M., Okuno, E., Kido, R., (1992) in: *Advances in Tryptophan Res.* Fujita Health University Press, Toyoake, Japan.
- [19] L. Benatti, M.B. Saccardo, M. Dani, G. Nitti, M. Sassano, R. Lorenzetti, D.A. Lippi, M. Soria, *Eur. J. Biochem.* 183 (1989) 465–470.
- [20] M.S. Fabbrini, B. Valsasina, G. Nitti, L. Benatti, A. Vitale, *FEBS Lett.* 286 (1991) 91–94.
- [21] S. Toné, Y. Katoh, H. Fujimoto, S. Togashi, M. Yanazawa, Y. Kato, T. Higashinakagawa, *Differentiation* 44 (1990) 62–68.
- [22] Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
- [23] J. Kawai, E. Okuno, R. Kido, *Enzyme* 39 (1988) 181–189.
- [24] D.G. Abraham, A.J.L. Cooper, *Anal. Biochem.* 197 (1991) 421–427.
- [25] F. Takeuchi, R. Tsubouchi, M. Yoshino, Y. Shibata, *Biochim. Biophys. Acta* 1252 (1995) 185–188.
- [26] D. Alberati-Giani, R. Buchli, P. Malherbe, C. Broger, G. Lang, C. Kohler, W. Lahm, A. Cesura, *Eur. J. Biochem.* 239 (1996) 460–468.
- [27] A.J.L. Cooper, *Adv. Pharmacol.* 27 (1994) 71–113.
- [28] N.J. Patel, J. Fullone, M.W. Anders, *Mol. Brain Res.* 17 (1993) 53–58.